

Table S1. Comparison of the baseline characteristics between the 25 patients who initiated statins and the 237 who did not

Characteristic	Statins	No statins	Total
	(n = 25)	(n = 237)	(N = 262)
Male sex, No. (%)	22 (88)	180 (75.9)	202 (77.1)
Age, y, median (IQR) (baseline)	50.6 (47.5 - 53)	49.2 (46 - 52.6)	49.2 (46.1 - 52.6)
BMI (n=226), median (IQR)	24.5 (22.7 - 28.3)	24.4 (21.7 - 26.7)	24.4 (21.8 - 26.9)
Prior injection drug use, No. (%)	20 (80)	184 (77.6)	204 (77.9)
Methadone therapy, No. (%)	4 (16)	29 (12.2)	33 (12.6)
CDC disease category C, No. (%) ^a	8 (32)	64 (27)	72 (27.5)
CD4 ⁺ , nadir, cells/mm ³ , median (IQR)	140 (44 - 260)	171 (84 - 251)	165 (78 - 251)
cART during anti-HCV treatment, No. (%)	25 (100)	232 (97.9)	257 (98.1)
SVR	16 (64)	147 (62)	163 (62.2)
CD4 ⁺ , baseline, cells/mm ³ , median (IQR)	604 (390 - 770)	540 (377 - 802)	541 (384 - 792)
Undetectable HIV-RNA load at baseline, No. (%)	21 (84)	207 (87.3)	228 (87)
Prior anti-HCV therapy, No. (%)	2 (8)	29 (12.2)	31 (11.8)
HCV genotype, No. (%)			
1	13 (52)	156 (66.4)	169 (64.5)
2	1 (4)	4 (1.7)	5 (1.9)
3	6 (24)	40 (17)	46 (17.6)
4	3 (12)	18 (7.7)	21 (8)
Other/mixed	2 (8)	17 (7.2)	19 (7.3)
Unknown	0 (0)	2 (0)	2 (0.8)
HCV-RNA, Log ₁₀ IU/mL, median (IQR)	6.5 (5.9 - 6.9)	6.3 (5.9 - 6.7)	6.3 (5.9 - 6.7)
HBsAg positivity, No. (%)	2 (8)	6 (2.5)	8 (3.1)
Liver stiffness (n=215), kPa, median (IQR)	11.7 (6.4 - 15.4)	12.5 (8.6 - 21.1)	12 (8.4 - 21)
Liver stiffness > 12.5, No. (%)	11 (44)	115 (48.5)	126 (48.1)
Liver cirrhosis, No. (%) (METAVIR 4 or TE>12.5)	12 (48)	119 (50.2)	131 (50)
Current alcohol intake > 50 g/d, No. (%)	0 (0)	7 (3)	7 (2.7)
Diabetes mellitus, No. (%)	3 (12)	20 (8.4)	23 (8.8)
Current smoking, No. (%)	17 (68)	162 (68.4)	179 (68.3)
Arterial hypertension, No. (%)	9 (36)	27 (11.4) *	36 (13.7)
Coronary artery disease, No. (%)	3 (17.6)	26 (11)	29 (13.2)
Anti-HCV therapy, No. (%)			
Peg-IFN + RBV	7 (28)	80 (33.8)	87 (33.2)
Peg-IFN + RBV + HCV protease inhibitor	10 (40)	117 (49.5)	127 (48.4)
Peg-IFN + RBV + daclatasvir	1 (4)	14 (5.9)	15 (5.7)
Sofosbuvir + RBV	7 (28)	26 (11)	33 (12.6)

* $P < .05$ compared with the Statins group

Abbreviations: SVR, sustained viral response; IQR, interquartile range; BMI, body mass index; CDC, Centers for Disease Control and Prevention; cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; HCV, hepatitis C virus; RNA, ribonucleic acid; HBsAg, hepatitis B surface antigen; Peg-IFN, pegylated interferon alpha; RBV, ribavirin; TE, transient elastography.


Table S2. Changes in biomarkers of inflammation and endothelial dysfunction from baseline to week 96 in patients with and without sustained viral response.

Biomarker – least square mean (SEM)	SVR	Non-SVR	P
TNF α (pg/mL), N=171			
Baseline	3.91 (0.35)	2.41 (0.48)	0.524
Week 96	4.52 (0.38)	3.68 (0.93)	
IL-1 β (pg/mL); N=171			
Baseline	2.07 (0.21)	1.64 (0.29)	0.763
Week 96	1.84 (0.23)	1.59 (0.55)	
IL-6 (pg/mL); N=171			
Baseline	7.63 (0.90)	8.81 (1.25)	0.823
Week 96	6.27 (0.96)	6.98 (2.08)	
IL-8 (pg/mL); N=175			
Baseline	8.85 (0.89)	10.4 (1.19)	0.577
Week 96	6.40 (1.00)	6.52 (2.24)	
sVCAM-1 (ng/mL); N=177			
Baseline	2142 (176)	2559 (233)	0.934
Week 96	1628 (191)	2001 (455)	
sICAM-1 (ng/mL); N=177			
Baseline	3941 (1071)	7515 (1424)	0.156
Week 96	3357 (1157)	2737 (2672)	

* P value refers to the significance of the interaction (i.e., the impact of SVR on the time-course of the variable).

Abbreviations: SVR, sustained viral response; IQR, interquartile range; IL-1 β , interleukin 1 beta; TNF α , tumor necrosis factor alpha; IL-6, interleukin 6; IL-8, interleukin 8; sICAM-1; soluble intercellular adhesion molecule-1; sVCAM-1; soluble vascular cell adhesion molecule-1.

Figure S1. Changes in serum lipid concentrations from baseline to week 96 in patients with (N=141) and without (N=86) SVR.



Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; BL, baseline; wk, week.